Not applicableStudy completedNCT02620254What this trial is testingMast Cell Connect: A Registry for Patients With MastocytosisWho this might be right forMastocytosis Blueprint Medicines Corporation 743
Large-scale testing (Phase 3)UnknownNCT01602939What this trial is testingCladribine Plus Pegylated Interpheron Alfa-2a in Systemic MastocytosisWho this might be right forSystemic Mastocytosis Hospital Virgen de la Salud 10
Not applicableStudy completedNCT02380222What this trial is testingPatient-Reported Outcome Questionnaire for Systemic MastocytosisWho this might be right forAggressive Systemic Mastocytosis (ASM)SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD)Mast Cell Leukemia (MCL)+2 more Adelphi Values LLC 5
Not applicableAvailableNCT06915766What this trial is testingExpanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic MastocytosisWho this might be right forSystemic Mastocytoses, IndolentSystemic Mastocytoses, Aggressive Cogent Biosciences, Inc.
Early research (Phase 1)Active Not RecruitingNCT05362773What this trial is testingMGD024 in Patients With Relapsed or Refractory Hematologic MalignanciesWho this might be right forLeukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more MacroGenics 130
Testing effectiveness (Phase 2)Ended earlyNCT03214666What this trial is testingGTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological MalignanciesWho this might be right forHigh-risk Myelodysplastic SyndromesAcute Myelogenous LeukemiaSystemic Mastocytosis+1 more GT Biopharma, Inc. 12
Not applicableStudy completedNCT04695431What this trial is testingRetrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSMWho this might be right forAdvanced Systemic MastocytosisAggressive Systemic MastocytosisSystemic Mastocytosis With an Associated Hematological Neoplasm+1 more Blueprint Medicines Corporation 317
Testing effectiveness (Phase 2)Ended earlyNCT02415608What this trial is testingIbrutinib in Treating Patients With Advanced Systemic MastocytosisWho this might be right forAggressive Systemic MastocytosisMast Cell LeukemiaSystemic Mastocytosis Jason Robert Gotlib 4
Not applicableStudy completedNCT00769587What this trial is testingThalidomide in Treating Patients With Relapsed or Progressive Systemic MastocytosisWho this might be right forNon Neoplastic ConditionPrecancerous Condition Centre Hospitalier Universitaire, Amiens
Testing effectiveness (Phase 2)Study completedNCT01807598What this trial is testingBrentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell LeukemiaWho this might be right forAggressive Systemic MastocytosisMast Cell LeukemiaSystemic Mastocytosis Jason Robert Gotlib 10
Testing effectiveness (Phase 2)Looking for participantsNCT04996875What this trial is testing(Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisWho this might be right forAdvanced Systemic Mastocytosis (AdvSM)SM With an Associated Hematologic Neoplasm (SM-AHN)Mast Cell Leukemia (MCL)+1 more Cogent Biosciences, Inc. 140
Early research (Phase 1)Study completedNCT02571036What this trial is testingA Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced MalignanciesWho this might be right forGastrointestinal Stromal TumorsAdvanced Systemic MastocytosisAdvanced Cancers Deciphera Pharmaceuticals, LLC 282
Not applicableNo Longer AvailableNCT05219266What this trial is testingManaged Access Programs for PKC412, MidostaurinWho this might be right forFMS-Like Tyrosine Kinase 3 (FLT3)-Mutated Acute Myeloid LeukemiaAcute Myeloid LeukemiaAggressive Systemic Mastocytosis+2 more Novartis Pharmaceuticals
Not applicableStudy completedNCT00112593What this trial is testingFludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAcute Undifferentiated LeukemiaAdult Acute Lymphoblastic Leukemia in Remission+176 more Fred Hutchinson Cancer Center 5
Early research (Phase 1)Study completedNCT00890747What this trial is testingSunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral TherapyWho this might be right forAccelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAcute Undifferentiated Leukemia+82 more National Cancer Institute (NCI) 42
Early research (Phase 1)Ended earlyNCT05609942What this trial is testingStudy of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic MalignanciesWho this might be right forAdvanced Systemic Mastocytosis Blueprint Medicines Corporation 9
Testing effectiveness (Phase 2)Study completedNCT03580655What this trial is testing(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisWho this might be right forAdvanced Systemic MastocytosisAggressive Systemic MastocytosisSystemic Mastocytosis With an Associated Hematologic Neoplasm+1 more Blueprint Medicines Corporation 107
Testing effectiveness (Phase 2)Study completedNCT00233454What this trial is testingPhase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell LeukemiaWho this might be right forSystemic Mastocytosis, Aggressive (ASM)Leukemia, Mast CellHematological Non-mast Cell Lineage Disease (AHNMD) Jason Robert Gotlib 26
Post-approval studies (Phase 4)Looking for participantsNCT06748001What this trial is testingAvapritinib Rollover StudyWho this might be right forMastocytosis, Systemic Blueprint Medicines Corporation 60
Early research (Phase 1)Study completedNCT02561988What this trial is testing(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesWho this might be right forAggressive Systemic MastocytosisSystemic Mastocytosis-associated Hematologic Non-mast Cell DiseaseMast Cell Leukemia+1 more Blueprint Medicines Corporation 86